On March 9, 2026, Hims & Hers Health announced a strategic partnership with pharmaceutical giant Novo Nordisk that will bring branded Ozempic (semaglutide) injections and Wegovy pills and injections onto the Hims & Hers telehealth platform. Concurrent with the announcement, Novo Nordisk dropped its patent infringement lawsuit against Hims & Hers — a suit filed in February 2026 over the company's sale and marketing of compounded GLP-1 weight loss drugs.

Why It Matters

While the Novo Nordisk deal is primarily about GLP-1 weight loss drugs, it has profound implications for Hims' sexual health business. The company built its brand on destigmatizing ED treatment through telehealth — and that franchise now sits inside a much larger, more legitimate healthcare platform. The stock surge and analyst upgrades signal that Wall Street is finally valuing Hims as a healthcare company rather than a "bro wellness" play, which could open doors for deeper investment in sexual health R&D and expanded product lines.

Under the agreement, Hims will offer access to injectable and oral semaglutide products at the same price as other telehealth platforms, while ceasing to advertise compounded GLP-1 drugs on its platform or in its marketing. Compounded versions will be limited to cases where FDA-approved options don't meet clinical needs. CEO Andrew Dudum framed the pivot as a win: "FDA-approved GLP-1 treatments are now more accessible, with greater affordability."

Wall Street responded with enthusiasm. HIMS stock surged approximately 57% in the week following the announcement — its best week on record. Major firms including Goldman Sachs and JP Morgan upgraded the stock from "Neutral" to "Overweight," with analysts noting that the deal transforms Hims from a scrappy telehealth disruptor into a legitimate pharmaceutical distribution partner.

Warren Templeton of Health2047 called the collaboration a "vital lifeline" for Hims & Hers following mounting regulatory pressure on compounded drugs. The deal effectively ends the company's "compounding era" and positions it as a branded partner to Big Pharma, though its legacy sexual health segments — ED treatments, hair loss, and skincare — continue to provide high-margin stability with new innovations in topical ED treatments.

Sources

Update — 2026-03-15

Initial entry — story first created.

Update — 2026-03-19

Hims & Hers' transformation from telehealth upstart to global healthcare platform accelerated dramatically in the weeks following the Novo Nordisk deal. On February 19, 2026, the company announced a definitive agreement to acquire Eucalyptus, an Australian-based international digital health company, for up to $1.15 billion — by far the largest acquisition in Hims' history. Approximately $240 million will be paid in cash at closing, with the remainder structured as guaranteed deferred payments over 18 months and earnout payments through early 2029. Eucalyptus operates five digital healthcare clinics across Australia, Japan, Germany, Canada, and the UK, including women's weight-loss brand Juniper, men's health platforms Pilot and Compound, and reproductive healthcare brand Kin. Eucalyptus boasts an annual revenue run-rate exceeding $450 million with triple-digit year-over-year growth throughout 2025. CEO Tim Doyle will become SVP of International at Hims.

The deal came just weeks after the FDA issued warning letters to 30 telehealth companies on March 3 over misleading marketing of compounded GLP-1 drugs — the agency's second wave of enforcement since September 2025. While Hims was not named specifically, the crackdown underscored the urgency of the company's pivot toward branded drugs via the Novo Nordisk partnership.

FY 2025 financials paint a company on a tear: revenue hit $2.35 billion (up 59% YoY), and the company posted its second consecutive year of GAAP net income at $128.4 million. Citigroup upgraded HIMS from Sell to Neutral, raising its price target from $13.25 to $24.00, while Deutsche Bank lifted its target from $25.00 to $28.00. However, profit-taking set in by March 12 (HIMS closed down 7.88%), and insider selling continued — COO Michael Chi sold 97,289 shares (~$2.4M) on March 17.

New Sources

Update — 2026-03-22

Hims & Hers continued its breakneck transformation this week. On March 21, the company officially launched Novo Nordisk's Wegovy oral pill on its platform, with CEO Andrew Dudum calling it "the fastest GLP-1 launch in history." The move cements the Novo partnership announced March 9 and marks Hims' definitive pivot from compounded to branded pharmaceuticals.

In a quieter but potentially significant expansion of its men's health portfolio, Hims partnered with Marius Pharmaceuticals to offer KYZATREX — an FDA-approved needle-free oral testosterone replacement therapy shown to restore testosterone levels in up to 96% of men. The partnership extends Hims' sexual health franchise beyond ED into testosterone replacement, a market historically dominated by injections and topical gels.

However, legal headwinds persist. On March 20, shareholder litigation firm Kahn Swick & Foti announced a fiduciary duty investigation into Hims, and shares dropped approximately 7% on March 18 amid continued scrutiny of the company's prior compounded drug practices. The stock remains volatile despite Barclays raising its price target to $29 following the Novo deal.

New Sources